LETTER

187

A good first step for ERAS in otolaryngoiatric field, but it is not enough

This article was published in the following Dove Medical Press journal: Therapeutics and Clinical Risk Management

Massimiliano Pelli¹ Luigi Maggi² Monica Rocco¹

Department of Anesthesia and Intensive Care, La Sapienza University of Rome, Rome, Italy; ²Department of Emergency, ASL Roma 5, Hospital Parodi Delfino of Colleferro, Colleferro, Italy

Correspondence: Luigi Maggi Department of Emergency, ASL Roma 5, Hospital Parodi Delfino of Colleferro, Leno Road Number 7, Nettuno, 00048, Rome, Italy Email maggi.medicina@libero.it

Dear editor

We read thoroughly the article by Liao et al¹ "Decreased hospital charges and postoperative pain in septoplasty by application of enhanced recovery after surgery" and we found it very interesting and innovative, given the low level of evidence about the application of the enhanced recovery after surgery (ERAS) protocol in otolaryngologic field. Nevertheless, there are some points that we have focused on since they remain unclear and decrease the scientific reliability of the results. First, we have noticed that the primary endpoint is not well defined, and this is reflected in the whole setting of the study: randomization method, allocation of the patients, statistical analysis, and results. Whilst perioperative management of the ERAS group is quite well described, however, the "common processing" of the control group remains undefined. In our opinion, for all these reasons, readers cannot fully understand the author's objective, thus making this study difficult to reproduce.

Moreover patients in the ERAS group were managed with local anesthesia and postoperative administration of oral nonsteroidal anti-inflammatories (NSAIDs), differently from the control group, which only received general anesthesia and no postoperative analgesia. This affects evaluation of real benefits of the innovative surgical approach, consisting of the avoidance of postoperative nasal filling and the use of a new nasal septum suture.

According to the study results, in the ERAS group there was a decrease in the hospital stay of 1.4 days (4.4 vs 5.8) compared with that in the control group. This positive result could be improved if we consider that other authors shortened more endoscopic septoplasty length of stay, having fewer long-stay patients (>48 hours).² In the present literature there are no adequate neither standardized studies about septoplasty costs analysis; indeed the author's aim to evaluate hospital charges is desirable. From this perspective, the choice of sedation anesthesia instead of general anesthesia in the ERAS group could be a suitable manner to reduce healthcare costs, total operation time, and postoperative complications.³

Disclosure

The authors report no conflicts of interest in this communication.



Commercial use of this work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/license/by-nc/3.0/). By accessing the work you
hereby accept the Terms. Non-commercial use of this work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission
for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

References

- Liao Z, Liao W, Tan KS, et al. Decreased hospital charges and postoperative pain in septoplasty by application of enhanced recovery after surgery. *Ther Clin Risk Manag.* 2018;14:1871–1877.
- 2. Champagne C. Endoscopic vs conventional septoplasty: a review of the literature. *Eur Ann Otorhinolaryngol Head Neck Dis*. 2016;133(1):43–46
- Hayrettin D. Septoplasty: under general or sedation anesthesia. Which is more efficacious? *Eur Arch Otorhinolaryngol*. 2014;271(9):2433–2436.

Authors' reply

Zhenpeng Liao,^{1,*} Wei Liao,^{1,*} Kai Sen Tan,^{2,*} Yueqi Sun,³ Aiqing Peng,¹ Yingxian Zhu,⁴ Haixin He,¹ Shuowei Yang,¹ Guangfu Xu,¹ Rongfei Su,¹ Jinyu Yao,³ Yunping Fan,¹ Qintai Yang,⁵ Haiyu Hong¹

¹Department of Otolaryngology, Allergy Center, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, People's Republic of China; ²Department of Otolaryngology, National University of Singapore, National University Health System, Singapore, Singapore; ³Department of Otolaryngology, Otorhinolaryngology Hospital, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China; ⁴Department of Anesthesiology, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, People's Republic of China; ⁵Department of Otolaryngology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China

Department of Otolaryngology, The Third Affiliated Hospital of Sun Yat-sen University, No 600, Tianhe Road, Guangzhou 510630, People's Republic of China Tel +86 137 2485 9848 Email yang.qt@163.com

Haiyu Hong

Department of Otolaryngology, Allergy Center, The Fifth Affiliated Hospital of Sun Yat-sen University, No 52, Meihua East Road, Zhuhai 519020, People's Republic of China Tel +86 138 2307 0089 Email honghy@sysu.edu.cn

Dear editor

Thank you for your comments and suggestions on this article.

Regarding the first point, the primary endpoint of this study was the length of hospital stay and postoperative pain. In addition, secondary endpoints such as nasal congestion, sleep disorder, anxiety and other conditions were also observed to improve in the study. With regards to "common processing" of the control group, it refers to the standard procedure of each region which varies and therefore it was difficult to describe in detail. A common denominator of the "common processing" is that the current hospital standard in the region for treating septoplasty was performed, without considering ERAS implementation. Therefore, the design suits the objective of the study in comparing treatment procedure with and without ERAS implementation.

In this study, the main evaluation is the application of ERAS as a means of avoiding the postoperative nasal filling that were found as a major contributor to post-operative discomfort. Therefore, the study did not account for comparison of the individual procedure. However, the point raised is an interesting one and we may look into individually evaluating the surgical procedure alone in the future with more comparable anesthetic procedure.

Thank you for the suggestion in further improving the hospitalization time. The modest decrease of hospitalization time in ERAS group by 1.4 days (4.4 vs 5.8) (<48 h) shows that our ERAS implementation is still in the preliminary stage and can still be further improved. The suggestions will surely contribute to the further refinement of the ERAS procedure in the otolaryngologic field.

Overall, we concur with the letter that the implementation of ERAS requires further refinement. The purpose of our study is to show the feasibility of ERAS implementation in the Otolaryngologic field and its potential benefits towards hospital charges and patient quality of life. We hope that we have sufficiently addressed the points in the letter and we welcome any future correspondence.

Disclosure

The authors report no conflicts of interest in this communication.

Dove Medical Press encourages responsible, free and frank academic debate. The content of the Therapeutics and Clinical Risk Management 'letters to the editor' section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Therapeutics and Clinical Risk Management editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press, accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.

Therapeutics and Clinical Risk Management

Publish your work in this journal

Therapeutics and Clinical Risk Management is an international, peerreviewed journal of clinical therapeutics and risk management, focusing on concise rapid reporting of clinical studies in all therapeutic areas, outcomes, safety, and programs for the effective, safe, and sustained use of medicines. This journal is indexed on PubMed Central, CAS, EMBase, Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: http://www.dovepress.com/therapeutics-and-clinical-risk-management-journal

Dovepress

189

Correspondence: Qintai Yang